Shefali Shah

MBA, Principal, Market Access Consulting

As a member of the market access consulting team, Shefali is responsible for guiding projects and developing strategic recommendations at Evidera. With over 15 years of pharmaceutical / biotech and consulting experience, Shefali fully understands the “evidence of value” challenges that our clients face and the best way to effectively use the wide array of expertise within Evidera to provide needed solutions. She has helped grow businesses at key clients by building innovative approaches, focused insights, and trusted relationships. She has delivered strategies for early market assets, pre-launch, and launch products across specialty and chronic diseases in neurosciences and a range of genetic disorders. For her clients, Shefali developed successful pricing, access, reimbursement, contracting, and launch strategies / programs.

Most recently, Shefali was Director, Market Access Effectiveness at Novo Nordisk. She built a team at Novo that was focused on connecting structured and unstructured data to develop differentiated insights and drive action. She has been an integral part of developing brand positioning and market potential of early assets based on their clinical strength and market’s willingness to pay. For assets in pre-launch phase, Shefali led the research and analysis to inform evidence generation plans, pricing and access strategies, value strategy, and patient support strategies. For products in market, she ensured value was captured for the brands through superior execution. Shefali led teams and projects that connected the Medical, Market Access, Brand, and Sales teams at Novo to develop differentiated value strategy, communication, and execution. During her career, she has also held senior positions at inVentive Health and Wyeth Consumer Healthcare. Shefali received her MBA at the NYU Stern School of Business and her BS in electrical engineering from Columbia University.